Shares rose to 335.60 Danish crowns, the biggest one-day rise since August 2023
Briefly, SURMOUNT-5 was a phase 3b multicenter, randomized, parallel-arm, open-label, active-controlled, 72-week trial that included adults aged 18 years or older, with a body mass index (BMI) 30 kg/m 2 or a BMI 27 kg/m 2 with at least one obesity-related complication (ORC, i.e., hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease), and relatively stable weight, not more than 5 kg change in 3 months before screening
No proprietary access, product samples, paid sponsorship by Omzo, or undisclosed compensation influenced this article's content beyond the affiliate relationship disclosed in the opening block
February 16, 2025 9:59 View More The Greatest Turnaround: Jacindas Inspiring Weight Loss and Health Transformation In this episode of our podcast, we had the pleasure of speaking with Jacinda, a patient at the Modern Thyroid Clinic and a participant
Netting neutrophils are major inducers of type I IFN production in pediatric systemic lupus erythematosus
